Asako Nagata
Pfizer (United States)(US)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Advanced Breast Cancer Therapies, Computational Drug Discovery Methods, Prostate Cancer Treatment and Research, HER2/EGFR in Cancer Research
Most-Cited Works
- → Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance(2016)414 cited
- → Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance(2013)277 cited
- → Expanding control of the tumor cell cycle with a CDK2/4/6 inhibitor(2021)172 cited
- → Discovery of PF-06873600, a CDK2/4/6 Inhibitor for the Treatment of Cancer(2021)112 cited
- → Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants(2016)93 cited
- → Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR(2017)89 cited
- → Protein redox chemistry: post-translational cysteine modifications that regulate signal transduction and drug pharmacology(2014)69 cited
- → Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists(2011)67 cited
- → Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors(2018)52 cited
- → Discovery of Potent, Selective, and Peripherally Restricted Pan-Trk Kinase Inhibitors for the Treatment of Pain(2018)38 cited